Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

NCT01871766 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

115

Enrollment

OTHER

Sponsor class

Conditions

Rhabdomyosarcoma

Interventions

DRUG: Vincristine
DRUG: Dactinomycin
DRUG: Cyclophosphamide
PROCEDURE: Surgical Resection
PROCEDURE: Radiation
DRUG: Bevacizumab
DRUG: Sorafenib
DRUG: Myeloid Growth Factor
PROCEDURE: Lymph Node Sampling
DRUG: Irinotecan
DRUG: Ifosfamide
DRUG: Etoposide
DRUG: Etoposide Phosphate
DRUG: Doxorubicin
DRUG: Dexrazoxane
DRUG: ^1^1C-methionine

Sponsor

St. Jude Children's Research Hospital